Katelyn Ponsoll, PA
Payments from drug & device makers
Across 321 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Dexcom, Inc.$751
- Lilly USA, LLC$540
- AbbVie$402
- Amgen$382
- Madrigal Pharmaceuticals$317
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,25799%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $1,741 |
| Dexcom, Inc. | 74 | $751 |
| Lilly USA, LLC | 26 | $540 |
| AbbVie | 23 | $402 |
| Amgen(2 entities) | 15 | $382 |
| Madrigal Pharmaceuticals | 5 | $317 |
| Tandem Diabetes Care, Inc. | 8 | $246 |
| AstraZeneca | 11 | $243 |
| Medtronic | 2 | $162 |
| Cequr Corporation | 4 | $150 |
| Merck | 8 | $121 |
| Xeris Pharmaceuticals, Inc. | 7 | $116 |
| Corcept Therapeutics | 6 | $111 |
| Insulet Corporation | 3 | $82 |
| Amarin Pharma, Inc. | 5 | $79 |
| Amneal Pharmaceuticals LLC | 4 | $77 |
| Azurity Pharmaceuticals, Inc. | 5 | $76 |
| Abbott | 4 | $68 |
| Recordati_rare_diseases_inc. | 4 | $56 |
| Pfizer | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Exact Sciences | 2 | $47 |
| Bayer | 3 | $47 |
| EUSA Pharma (US) LLC | 3 | $42 |
| Boehringer Ingelheim | 3 | $42 |
| Tolmar, Inc. | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| GSK | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$293
- Ozempic$228
- MINIMED 780G$137
- Wegovy$125
- MOUNJARO$125
- DEXCOM G6 TRANSMITTER$125
- Norditropin$125
- t:slim X2 Insulin Pump with Control-IQ$124
- EVENITY$114
How this compares
$6,313 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $85,180 |
| JardianceEmpagliflozin | 42 | $46,838 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $25,583 |
| MounjaroTirzepatide | 19 | $23,280 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $15,906 |
| FarxigaDapagliflozin Propanediol | 11 | $14,016 |
| TradjentaLinagliptin | 20 | $13,069 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,752 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $6,062 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 45 | $4,571 |
| SynthroidLevothyroxine Sodium | 37 | $3,673 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 24 | $2,605 |
| Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp | 13 | $922 |
| Levothyroxine Sodium | 79 | $821 |
| Metformin Hcl ErMetformin Hcl | 34 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog Mix 70-30 | $1,741 | $86,10288 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $59,90762 claims |
| Lilly USA, LLCMounjaro | $540 | $23,28019 claims |
| AstraZenecaFarxiga | $243 | $14,01611 claims |
| AbbVieSynthroid | $402 | $3,67337 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $77 | $1,00295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Erie
- Cory DavidsonErie$119K
- Emily ScavellaErie$13K
- Amy DudasErie$12K
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.